Keudell Morrison Wealth Management Acquires New Position in Johnson & Johnson $JNJ

Keudell Morrison Wealth Management acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 8,722 shares of the company’s stock, valued at approximately $1,805,000.

Several other large investors also recently bought and sold shares of the business. Plancorp LLC grew its stake in Johnson & Johnson by 0.3% during the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock valued at $3,288,000 after acquiring an additional 45 shares in the last quarter. Baron Silver Stevens Financial Advisors LLC grew its stake in Johnson & Johnson by 0.8% during the 4th quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,645 shares of the company’s stock valued at $1,168,000 after acquiring an additional 45 shares in the last quarter. WealthCollab LLC grew its stake in Johnson & Johnson by 4.7% during the 4th quarter. WealthCollab LLC now owns 1,015 shares of the company’s stock valued at $210,000 after acquiring an additional 46 shares in the last quarter. MMA Asset Management LLC grew its stake in Johnson & Johnson by 1.3% during the 4th quarter. MMA Asset Management LLC now owns 3,600 shares of the company’s stock valued at $745,000 after acquiring an additional 46 shares in the last quarter. Finally, Vista Investment Partners II LLC grew its stake in Johnson & Johnson by 1.2% during the 4th quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company’s stock valued at $789,000 after acquiring an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson said its immunology drug nipocalimab was approved in China, expanding the company’s international growth opportunity and adding to its pipeline momentum. Reuters: Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation device for calcified coronary artery disease, reinforcing growth in its medtech division and showing continued product innovation. Yahoo Finance: Johnson & Johnson (JNJ) Unveils Next-Gen Catheter for Coronary Artery Disease
• Positive Sentiment: Reports highlighting Johnson & Johnson as a defensive growth stock and a top long-term pick may be supporting sentiment, especially as investors look for steadier names amid market volatility. Insider Monkey: Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Neutral Sentiment: Several market commentaries and stock reports referenced J&J alongside other dividend and healthcare names, but these pieces did not provide new company-specific catalysts. Yahoo Finance: Johnson & Johnson Outperforms Broader Market

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, April 15th. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. Barclays boosted their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Guggenheim boosted their target price on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a report on Monday, April 20th. Finally, Argus boosted their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $231.69 on Friday. The firm’s 50 day moving average price is $234.19 and its 200-day moving average price is $223.20. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71. The firm has a market cap of $557.73 billion, a P/E ratio of 26.79, a P/E/G ratio of 2.25 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period in the prior year, the business posted $2.77 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.12%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.